TP53 Gene: Li-Fraumeni Syndrome, Cancer Risks, and What to Do
Medically reviewed by LifeShield Medical Team, Board-Certified Genetic Counselors & Clinical Advisors
Last updated February 20, 2026
Key Takeaways
- TP53 is often called the "guardian of the genome" because it controls cell growth, DNA repair, and programmed cell death. Mutations cause Li-Fraumeni syndrome.
- Li-Fraumeni syndrome carries one of the highest hereditary cancer risks, with up to a 90–95% lifetime risk of developing cancer.
- TP53 mutations are associated with a wide spectrum of cancers including breast cancer, sarcomas, brain tumors, adrenocortical carcinoma, and leukemia.
- Cancers in TP53 carriers often occur at very young ages, including childhood, and multiple primary cancers are common.
- Whole-body MRI screening (annually) is now recommended for TP53 carriers and has been shown to detect cancers at earlier, more treatable stages.
TP53 In Plain English
The TP53 gene makes a protein called p53, which is sometimes called the "guardian of the genome." Its job is to monitor your cells and decide what should happen when something goes wrong. If a cell’s DNA is damaged, p53 can pause cell growth to allow repairs, activate repair processes, or instruct the cell to self-destruct if the damage is too severe to fix. When TP53 is mutated, cells with serious DNA damage can survive and continue dividing, which dramatically increases the risk of cancer developing throughout the body.
Because p53 protects against cancer in virtually every tissue type, inheriting a TP53 mutation leads to Li-Fraumeni syndrome, a condition in which cancer can develop in many different organs and at very young ages. The breast cancer risk in TP53 carriers is comparable to that seen in BRCA1 and BRCA2 carriers, though TP53-associated breast cancers tend to occur at younger ages. Another hereditary syndrome with overlapping features is Cowden syndrome (caused by PTEN mutations), which also carries a high breast cancer risk and multi-organ involvement. While this diagnosis can feel overwhelming, advances in screening, particularly whole-body MRI, have significantly improved early detection and outcomes for carriers. For a broader understanding of inherited cancer syndromes, see our guide on hereditary cancer screening.
If you receive a positive TP53 result, our guide on what to do after a positive genetic test result outlines evidence-based next steps. For help interpreting different result types, see our resource on understanding genetic test results. Given the 50% chance of passing a TP53 mutation to each child and the potential for childhood cancers, cascade testing for family members is especially important for TP53 carriers. For guidance on navigating the counseling process, see what to expect from genetic counseling.
Cancer Risks Associated with TP53 Mutations
| Cancer Type | Lifetime Risk | General Population | Source |
|---|---|---|---|
| Breast cancer (often premenopausal) | Up to 85% (women) | 12.9% | NCCN v3.2025; Mai et al., J Clin Oncol 2016 |
| Soft tissue sarcoma | Up to 15% | < 0.4% | NCCN v3.2025; Mai et al., J Clin Oncol 2016 |
| Osteosarcoma | Up to 10% | < 0.1% | NCCN v3.2025 |
| Brain tumors | Up to 6% | 0.6% | NCCN v3.2025 |
| Adrenocortical carcinoma | Up to 5% | < 0.02% | NCCN v3.2025 |
| Leukemia and lymphoma | Elevated | 1.6% | NCCN v3.2025 |
Who Should Consider TP53 Testing?
NCCN recommends TP53 genetic testing for individuals with a personal history of cancer consistent with Li-Fraumeni syndrome, including early-onset breast cancer (before age 31), childhood sarcoma, adrenocortical carcinoma at any age, or multiple primary cancers. Testing is also recommended when a known TP53 mutation exists in the family or when family history meets classic or Chompret criteria for LFS.
Should You Get Tested?
Free 60-second screener based on NCCN guidelines — no account needed
Check Your Eligibility →Questions to Ask Your Genetic Counselor About TP53
- What specific TP53 variant do I have, and is it associated with particular cancer types?
- How should my screening schedule differ from standard Li-Fraumeni recommendations given my family history?
- Where can I access whole-body MRI screening, and how is it covered by insurance?
- What precautions should I take regarding radiation exposure in medical settings?
- Should I consider preventive mastectomy given my breast cancer risk?
- How should I approach screening for my children who may be at risk?
- Are there clinical trials for TP53 carriers or Li-Fraumeni syndrome?
What a TP53 Result Means for Your Family
TP53 mutations follow autosomal dominant inheritance, meaning each child of a carrier has a 50% chance of inheriting the mutation. Given the extremely high cancer risk and potential for childhood cancers, cascade testing of family members is strongly recommended. Children of carriers may benefit from screening programs beginning in childhood. Because 7–20% of TP53 mutations are de novo, even individuals without a family history of Li-Fraumeni syndrome can be carriers and pass the mutation to their children.
Inheritance Pattern: Autosomal dominant
Prevalence: Li-Fraumeni syndrome affects approximately 1 in 5,000–20,000 individuals; 7–20% are de novo mutations
Management Options If Positive:
- Annual whole-body MRI (with diffusion-weighted imaging)
- Annual breast MRI starting at age 20 (women)
- Annual dermatologic examination
- Annual comprehensive physical examination
- Discussion of risk-reducing mastectomy (women)
- Colonoscopy every 2–5 years starting at age 25
- Minimize ionizing radiation exposure (avoid CT scans when possible)
- Brain MRI annually
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is based on published NCCN clinical guidelines and peer-reviewed research. Always consult a qualified healthcare provider for medical decisions. LifeShield content is reviewed by board-certified genetic counselors.